CN Patent

CN110662534A — 包含(e)-4-(2-(氨基甲基)-3-氟烯丙基氧基)-n-叔丁基苯甲酰胺的药物组合物和药物剂型，其制备方法、治疗方法及用途

Assigned to Boehringer Ingelheim International GmbH · Expires 2020-01-07 · 6y expired

What this patent protects

本发明涉及包含具有化学结构(I)即(E)‑4‑(2‑(氨基甲基)‑3‑氟烯丙基氧基)‑N‑叔丁基苯甲酰胺的药物组合物或其药学上可接受的盐作为活性药学成分的药物组合物，特别涉及包含(E)‑4‑(2‑(氨基甲基)‑3‑氟烯丙基氧基)‑N‑叔丁基苯甲酰胺盐酸盐的药物组合物，涉及药物剂型，涉及它们的制备、它们的用途以及用于治疗性治疗的方法。

USPTO Abstract

本发明涉及包含具有化学结构(I)即(E)‑4‑(2‑(氨基甲基)‑3‑氟烯丙基氧基)‑N‑叔丁基苯甲酰胺的药物组合物或其药学上可接受的盐作为活性药学成分的药物组合物，特别涉及包含(E)‑4‑(2‑(氨基甲基)‑3‑氟烯丙基氧基)‑N‑叔丁基苯甲酰胺盐酸盐的药物组合物，涉及药物剂型，涉及它们的制备、它们的用途以及用于治疗性治疗的方法。

Drugs covered by this patent

Patent Metadata

Patent number: CN110662534A
Jurisdiction: CN
Classification: —
Expires: 2020-01-07
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.